Statins and cancer risk: a meta-analysis

Citation

(2006), "Statins and cancer risk: a meta-analysis", Clinical Governance: An International Journal, Vol. 11 No. 3. https://doi.org/10.1108/cgij.2006.24811cae.005

Statins and cancer risk: a meta-analysis

Summaries of abstracts from DARE (Database of Abstracts of Reviews of Effects)About DAREDARE is a key resource for answering questions about the effects of health care interventions, whether such questions arise from practice or when making commissioning decisions. The database is unique in that it contains abstracts of systematic reviews that have been quality-assessed. Each abstract includes a summary of the review together with a short critical commentary about the overall quality.DARE is produced by the Centre for Reviews and Dissemination, is updated monthly and is publicly available free of charge via the internet at: www.york.ac.uk/inst/crd/crddatabases.htm

DARE summariesStatins and cancer risk: a meta-analysisK.M. Dale, C.I. Coleman, N.N. Henyan, J. Kluger and C.M. WhiteJAMA2006Vol. 295No. 1pp. 74-80,

This review investigated the effect of statin therapy on cancer incidence and death from cancer. Studies that compared statins with placebo or standard treatment were eligible for inclusion. A total of 26 RCTs were included in the review. Atorvastatin was evaluated in three studies, cerivastatin in one, fluvastatin in three, lovastatin in three, pravastatin in 11 and simvastatin in five. The authors concluded that statins have no effect on cancer risk; this finding applied to all statins and all types of cancer investigated. This was a well-conducted review and the authors’ conclusions are likely to be reliable.

Read the abstract in full at: http://nhscrd.york.ac.uk/online/dare/20068005.htm